Biomarker data from Alligator Bioscience’s OPTIMIZE-1 trial presented at ASCO 2025 Annual Meeting

Lund, Sweden, 3 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that biomarker data from its OPTIMIZE-1 clinical trial were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

OPTIMIZE-1 is a Phase 1b/2 trial evaluating mitazalimab in combination with mFOLFIRINOX in first-line metastatic pancreatic cancer (mPDAC). The study has demonstrated strong clinical outcomes to date, including a ~30% survival rate at 24 months and a median overall survival of 14.9 months.

The biomarker analyses highlighted mitazalimab’s immunological mechanism of action, with immune activation in responding patients and gene signatures associated with clinical benefit and improved survival. These results support continued development of mitazalimab, including a planned confirmatory trial in mPDAC.

“ASCO continues to be a cornerstone event for clinical oncology, and it was a privilege to share our OPTIMIZE-1 data with the international community,” said Søren Bregenholt, CEO of Alligator Bioscience. “The high level of engagement and many productive meetings we’ve had during the conference further validate the growing interest in mitazalimab and its potential in pancreatic cancer.”

The presentation poster is available on Alligator’s website. Alligator’s participation at ASCO is part of its broader commitment to scientific collaboration and strategic business development.

Datum 2025-06-03, kl 08:45
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.